Although targeting the AR is initially clinically effective, most tumors become resistant to androgen-deprivation therapy (ADT) within a few years, due to progression to hormone-refractory or castration-resistant PCa (CRPC) [2]. This evidence concerns the gene AR and posterior cortical atrophy.